$2,716.21 travel Payment -- Regeneron Pharmaceuticals to Dr. Richard Brown

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Regeneron Pharmaceuticals made a $2.7K travel payment to Richard Brown, a Oncology specialist in San Francisco, CA. The payment was associated with Mounjaro. The payment of $2,716.21 to Dr. Richard Brown was for travel and lodging expenses. Regeneron Pharmaceuticals made this payment on May 1, 2025, related to Mounjaro. The payment was made to an Oncologist in San Francisco, CA.

Patient Guidance: What This Payment Means for You

This payment covered travel and lodging expenses, which may be associated with educational events or consultations related to a medication. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Travel and lodging payments to Oncologists can vary widely depending on the nature of the engagement, but this amount is within a typical range for professional development or advisory activities.

Regulatory Context: Sunshine Act Requirements

Payments for travel and lodging are reportable under the Sunshine Act, requiring disclosure of the recipient, payee, nature of payment, and associated drug or device.

Related Topics

This payment is related to the following healthcare transparency topics:

• cms-open-payments
• pharma-payments
• travel-and-lodging
• oncology
• regeneron-pharmaceuticals
• mounjaro

Understanding travel Payments

Travel and lodging payments cover transportation and accommodation expenses for physicians attending conferences, advisory board meetings, or speaking engagements sponsored by pharmaceutical companies. These payments can be substantial, particularly for international travel or multi-day events.

Frequently Asked Questions About This Payment

What was this $2.7K payment for?

This was a travel payment of $2.7K from Regeneron Pharmaceuticals to Richard Brown, categorized as "Travel and Lodging". It was associated with Mounjaro. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Richard Brown accept pharmaceutical money?

Yes, Richard Brown received this $2.7K payment from Regeneron Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Richard Brown's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this travel payment?

A travel payment of $2.7K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Oncology?

To compare this payment against Oncology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Oncology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Richard Brown's relationship with Regeneron Pharmaceuticals?

The payment covers travel and lodging, indicating potential educational or advisory activities. This $2.7K travel payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Oncology?

The specific drug Mounjaro is listed, suggesting a focus on its use or development.

What should patients do after learning about this payment?

This payment covered travel and lodging expenses, which may be associated with educational events or consultations related to a medication.

What else should I know about this travel payment?

The payment date is in the future (2025-05-01), which is unusual for reported payments.

Related Reports

• View Dr. Richard Brown's full payment report
• Regeneron Pharmaceuticals full spending report
• Browse all Oncology payments
• Browse all payments in California
• Search for other payments